Most Recent Research Study Investigates a New Class of Cancer Target for Mesothelioma Treatment and Diagnosis
Casa is delighted to hear the recent promising developments made by researchers for treatment for Mesothelioma – a cancer caused by asbestos exposure.
With the Support of National Charities Mesothelioma UK and Erase Meso, a six month project has advanced research into the diagnosis and treatment of Mesothelioma. The aim of this research project was to characterise a new target for cancer treatment, with the potential to benefit patients suffering from cancer caused by asbestos.
The research team focused on an enzyme known as ‘MDIG’, which acts as a cellular switch using oxygen. MIDG is known to be active in several types of tumors, but its role in Mesothelioma had not been explored prior to this research project.
Given MDIG’s influence on protein synthesis (a critical part of Mesothelioma survival), as well as the increased level of MDIG due to the patient’s exposure to silica and mineral dusts, researchers hypothesized that MDIG may significantly contribute to the development of Mesothelioma.
What they found:
Upon research, the team discovered high levels of MDIG and its cellular targets in laboratory grown Mesothelioma cells, and that its presence allows for maximum growth rate of these cancerous cells. These findings are pivotal and as a result, suggest that MDIG could be a promising new drug target for treatment of mesothelioma.
Through collaborations with chemists at the University of Oxford and Rome, researchers are well-positioned to target MDIG in their work as a treatment for Mesothelioma.
Paul Cook, founder of Erase Meso, commented: “I am immensely proud of the strides we are making in the fight against Mesothelioma. This groundbreaking research on MDIG represents a beacon of hope for patients and their families who have been affected by this devastating disease.”
Chief Executive of Mesothelioma UK, Liz Darlinson, added: “By identifying this new drug target, we have taken the first crucial step on the journey to finding a potential new treatment option for mesothelioma patients.”
Currently in the UK, over 2,700 people per year are diagnosed with Mesothelioma, with exposure to asbestos being responsible for up to 9/10 cases.
We know this number should be 0 – no one should be exposed to asbestos ever, but research developments like this provide hope for those suffering and their loved ones.
You can donate to Mesothelioma UK here, and Erase Meso here, to show your support for the incredible work in changing lives.
Are you concerned about asbestos in your premises? Contact us today for any advice, or a no obligation quote for an asbestos survey. Your safety is our first priority.
